쥐 모델에서 안구 표면 염증을 유도하는 방법

Executive Industry Relevance

This method establishes a murine model of ocular surface inflammation that recapitulates key pathophysiological features of dry eye disease, including meibomian gland dysfunction driven by neutrophil-derived aggNETs. It enables mechanistic interrogation of immune-mediated lipid secretion impairment, supporting target validation in ocular surface disorders. The model provides a reproducible system for evaluating therapeutic candidates that modulate neutrophil activity or aggNET formation in preclinical discovery.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Enables interrogation of Th cell-dependent cytokine and chemoattractant release as drivers of ocular surface inflammation.
• Scientific Value: Supports functional validation of neutrophil-derived aggNETs as mechanistic links between inflammation and meibomian gland obstruction.
• Scientific Value: Facilitates target de-risking by connecting immune activation to lipid secretion impairment in a disease-relevant system.

Screening & Assay Development

• Scientific Value: Generates quantifiable ocular exudates for downstream analysis of inflammatory mediators and neutrophil activity.
• Operational Value: Standardized immunization and challenge procedures enable reproducible induction of inflammation across study cohorts.
• Scientific Value: AggNET formation serves as a measurable biomarker of neutrophil extracellular trap activity in ocular tissue.

Translational & Preclinical Research

• Scientific Value: Models dry eye disease pathophysiology with immune-mediated meibomian gland dysfunction, supporting translational biomarker alignment.
• Operational Value: Provides a disease-relevant system for preclinical evaluation of compounds targeting neutrophil activation or ROS-mediated pathways.
• Strategic Value: Enables risk-adjusted advancement decisions by linking target modulation to reduction of aggNET-dependent gland obstruction.

Pipeline & Workflow Integration

The method fits within the discovery continuum from target validation through lead identification to preclinical efficacy testing in ocular surface inflammation models.

• Discovery Biology: Supports hypothesis testing of Th cell and neutrophil contributions to ocular surface pathology via defined immune stimulation.
• Screening: Delivers standardized inflammatory readouts including cytokine levels, neutrophil influx, and aggNET formation for compound screening.
• Analytics: Enables quantitative measurement of ocular exudates, ROS production, and chromatin decondensation as functional outputs.
• Translational Research: Connects immune mechanisms to lipid secretion impairment, supporting continuity to preclinical dry eye disease models.
• Enterprise Reuse: Establishes a reusable platform for immunogen-induced ocular inflammation applicable across multiple target classes.

Operational & Enterprise Impact

• Scientific Value: Provides mechanistic de-risking by defining the causal chain from Th cell activation to aggNET-mediated gland obstruction.
• Operational Value: Ensures reproducibility through standardized intraperitoneal immunization and ocular challenge protocols.
• Strategic Value: Improves go/no-go decisions by linking target engagement to reduction of neutrophil-driven pathophysiological endpoints.
• Portfolio Impact: Supports risk-adjusted prioritization of candidates that modulate neutrophil extracellular trap formation in ocular inflammation.

Implementation Considerations

• Requires expertise in murine handling, intraperitoneal injection, and ocular surface procedures.
• Dependent on sterile technique for immunogen preparation and ocular exudate collection.
• Necessitates access to fluorescence or microscopy tools for aggNET visualization and neutrophil quantification.
• Involves optimization of immunogen dose and timing to achieve consistent inflammation without excessive morbidity.
• Limited to murine models; interspecies differences in neutrophil biology may affect translational scaling.

Biopharma FAQs